Cytokinetics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cytokinetics and other ETFs, options, and stocks.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.

CEO

Robert I. Blum

CEORobert I. Blum

Employees

423

Employees423

Headquarters

South San Francisco, California

HeadquartersSouth San Francisco, California

Founded

1997

Founded1997

Employees

423

Employees423

CYTK Key Statistics

Market cap

5.79B

Market cap5.79B

Price-Earnings ratio

-9.11

Price-Earnings ratio-9.11

Dividend yield

—

Dividend yield—

Average volume

1.56M

Average volume1.56M

High today

$49.82

High today$49.82

Low today

$47.41

Low today$47.41

Open price

$47.83

Open price$47.83

Volume

1.64M

Volume1.64M

52 Week high

$110.25

52 Week high$110.25

52 Week low

$30.68

52 Week low$30.68

CYTK News

TipRanks 2d

Cytokinetics price target raised to $103 from $99 at Mizuho

Mizuho raised the firm’s price target on Cytokinetics (CYTK) to $103 from $99 and keeps an Outperform rating on the shares. The analyst updated models in the bi...

Investing.com 3d

Cytokinetics CEO Robert Blum sells shares for $252,750 - Investing.com

...

TipRanks 4d

Cytokinetics partnership demonstrates value of aficamten, says JMP Securities

Cytokinetics (CYTK) on Tuesday announced an exclusive licensing collaboration for aficamten in Japan with Bayer (BAYRY), which JMP Securities tells investors un...

Analyst ratings

79%

of 19 ratings

Buy

78.9%

Hold

21.1%

Sell